IT1249051B - Immunotossina da anticorpi monoclonali anti-cd5 - Google Patents

Immunotossina da anticorpi monoclonali anti-cd5

Info

Publication number
IT1249051B
IT1249051B ITMI910491A ITMI910491A IT1249051B IT 1249051 B IT1249051 B IT 1249051B IT MI910491 A ITMI910491 A IT MI910491A IT MI910491 A ITMI910491 A IT MI910491A IT 1249051 B IT1249051 B IT 1249051B
Authority
IT
Italy
Prior art keywords
immunotoxin
monoclonal antibodies
momordine
obtainable
monoclonal antibody
Prior art date
Application number
ITMI910491A
Other languages
English (en)
Inventor
Giulia Porro
Daniela Modena
Fiorenzo Stirpe
Gianni Gromo
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Priority to ITMI910491A priority Critical patent/IT1249051B/it
Publication of ITMI910491A0 publication Critical patent/ITMI910491A0/it
Priority to EP92904825A priority patent/EP0577612A1/en
Priority to PCT/EP1992/000338 priority patent/WO1992014491A1/en
Priority to AU12088/92A priority patent/AU1208892A/en
Publication of ITMI910491A1 publication Critical patent/ITMI910491A1/it
Application granted granted Critical
Publication of IT1249051B publication Critical patent/IT1249051B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Si descrive un'immunotossina ottenibile per coniugazione covalente della tossina di origine vegetale momordina a un anticorpo monoclonale anti-CD5.
ITMI910491A 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5 IT1249051B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITMI910491A IT1249051B (it) 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5
EP92904825A EP0577612A1 (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies
PCT/EP1992/000338 WO1992014491A1 (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies
AU12088/92A AU1208892A (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI910491A IT1249051B (it) 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5

Publications (3)

Publication Number Publication Date
ITMI910491A0 ITMI910491A0 (it) 1991-02-26
ITMI910491A1 ITMI910491A1 (it) 1992-08-26
IT1249051B true IT1249051B (it) 1995-02-11

Family

ID=11358745

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI910491A IT1249051B (it) 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5

Country Status (4)

Country Link
EP (1) EP0577612A1 (it)
AU (1) AU1208892A (it)
IT (1) IT1249051B (it)
WO (1) WO1992014491A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
CN111670052A (zh) * 2017-11-29 2020-09-15 美真达治疗公司 用于耗尽cd5+细胞的组合物和方法
KR20220003572A (ko) 2019-04-24 2022-01-10 하이델베르크 파마 리서치 게엠베하 아마톡신 항체-약물 결합체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363799A (en) * 1979-03-20 1982-12-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human T cells, and methods for preparing same
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
WO1986005098A1 (en) * 1985-03-04 1986-09-12 Dana-Farber Cancer Institute, Inc. Immunotoxin and method of making
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
JPH03503887A (ja) * 1988-02-03 1991-08-29 エクソウマ コーポレーション 自己免疫疾患に対する抗t細胞イムノトキシンの治療的使用
JPH03503164A (ja) * 1988-02-03 1991-07-18 エクソウマ コーポレーション 抗‐パンt‐細胞イムノトキシン組成物による免疫抑制
WO1989011871A1 (en) * 1988-06-01 1989-12-14 Cetus Corporation One-step chromatographic purification of immunotoxin conjugates using a thiophilic matrix

Also Published As

Publication number Publication date
ITMI910491A1 (it) 1992-08-26
EP0577612A1 (en) 1994-01-12
WO1992014491A1 (en) 1992-09-03
AU1208892A (en) 1992-09-15
ITMI910491A0 (it) 1991-02-26

Similar Documents

Publication Publication Date Title
DK0897983T3 (da) Antistoffer mod CD40-L
MY104946A (en) Antigen antibody conjugate.
EP0394277A4 (en) Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
ATE46084T1 (de) Immunotoxin-konjugate.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
ATE165515T1 (de) Immuntoleranzinduzierendes agens
DE69132055D1 (de) Ortsgenaue konjugatbildung zwischen immunglobulinen und nachweisbaren markierungsstoffen
ITRM920457A0 (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana.
BG40318A3 (en) Method for preparing imunoglobuline derivatives of vindezine
IT1249051B (it) Immunotossina da anticorpi monoclonali anti-cd5
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
GB2254326B (en) Monoclonal antibodies produced by in vitro immunization of lymphocytes
GB2192185B (en) Monoclonal antibodies to pseudomonas aeruginosa flagella
IT9019160A1 (it) Anticorpo monoclonale in grado di riconoscere uno specifico epitopo di glicosidi antraciclinici e ibridoma secernente tale anticorpo
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
EP0511300A4 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
NO174003C (no) Monoklonale menneskeantistoffer mot pseudomonas aeruginosa eksotoksin
ATE132906T1 (de) Neuartige antiidiotypische monoklonale antikörper
TW349995B (en) Monoclonal anti-IgM antibody conjugated to gelonin
DE69118780D1 (de) Monoklonaler Antikörper, der spezifisch mit dem humanen Perforin reagiert
FI923348A (fi) Laekemedel och foerfaranden foer kelandering av aids och aids-relaterade komplex (arc) med anvaendning av kolhydratantigener och antikroppar mot kolhydrater.
DK0493686T3 (da) Monoklonale antistoffer for glycolipid-kulhydratkæder
ITMI932667A1 (it) Metodo per la produzione di anticorpi monoclonali specifici per le chemochine

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960227